Literature DB >> 2533904

The metabolism of ondansetron.

D A Saynor1, C M Dixon.   

Abstract

The metabolism of ondansetron has been studied in rat, dog and man. In laboratory animals absorption of the compound across the gastrointestinal tract is rapid and extensive, but due to high first-pass metabolism, the oral systemic bioavailability is low (less than 10%). The high systemic clearance of ondansetron results in a very short half-life in rat and dog. The renal clearance of ondansetron is low, indicating that the major route of systemic clearance is by metabolism. Routes of excretion of drug-related material differ between laboratory animals and man - the major route in the rat and dog is via the bile, while in man the predominant route is via the urine. However, the routes of metabolism are qualitatively similar in all species, indicating that the species used in toxicological testing of ondansetron were appropriate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533904

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  13 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model.

Authors:  Fátima Ortega; Antonio Quintana; Elena Suárez; John C Lukas; Nerea Jauregizar; Leire de la Fuente; Maria Luisa Lucero; Ana Gonzalo; Aurelio Orjales; Rosario Calvo
Journal:  Pharm Res       Date:  2005-09-20       Impact factor: 4.200

Review 3.  Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

Authors:  Y F Sung
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 4.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

5.  PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Authors:  Rachel Huddart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

Review 6.  Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

7.  Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats.

Authors:  J M Quimby; R C Lake; R J Hansen; P J Lunghofer; D L Gustafson
Journal:  J Vet Pharmacol Ther       Date:  2013-12-16       Impact factor: 1.786

8.  The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.

Authors:  E I Ashforth; J L Palmer; A Bye; A Bedding
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

9.  Response of Htr3a knockout mice to antidepressant treatment and chronic stress.

Authors:  Vincent Martin; Armance Riffaud; Tevrasamy Marday; Charly Brouillard; Bernard Franc; Jean-Pol Tassin; Caroline Sevoz-Couche; Raymond Mongeau; Laurence Lanfumey
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

10.  The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.

Authors:  J C Blake; J L Palmer; N A Minton; A K Burroughs
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.